Literature DB >> 27873597

Detection of NDM-2-producing Acinetobacter baumannii and VIM-producing Pseudomonas aeruginosa in Palestine.

Isabella Sjölander1, Frank Hansen2, Abdelraouf Elmanama3, Rasha Khayyat4, Alaeddin Abu-Zant4, Ayman Hussein4, Adham Abu Taha4, Anette M Hammerum2, Oana Ciofu5.   

Abstract

The aim of this study was to screen for carbapenem-resistant Gram-negative bacteria in Palestine and subsequently to identify and investigate the mechanisms of resistance. For a period of 6 weeks, all Gram-negative isolates were collected from six Palestinian hospital laboratories and were tested for susceptibility using 10μg meropenem disks. Isolates showing resistance to meropenem were further investigated. The presence of carbapenemases was assessed by PCR. In addition, antimicrobial susceptibility testing, an efflux pump inhibitor assay and pulsed-field gel electrophoresis (PFGE) were performed. Isolates producing carbapenemases were further investigated by multilocus sequence typing (MLST). In total, 248 Gram-negative isolates were collected from the six laboratories. Among the 248 tested isolates, 15 Acinetobacter baumannii and 6 Pseudomonas aeruginosa were resistant to meropenem. One A. baumannii from Gaza produced NDM-2 and belonged to ST103. Thirteen of the carbapenem-resistant A. baumannii isolates possessed the intrinsic upregulated blaOXA-66 gene and one isolate carried blaOXA-51. All but one of the OXA-66-producing A. baumannii belonged to ST2; the remaining isolate belonged to ST183. One of the carbapenem-resistant P. aeruginosa was classified as VIM-4-producing and three were VIM-2-producing isolates. The three VIM-2-producing isolates belonged to three new sequences types (ST1562, ST1563 and ST1564). All of the carbapenemase-producing isolates were multiresistant non-fermenters. To the best of our knowledge, this is the first report on NDM-producing A. baumannii and VIM-producing P. aeruginosa from Palestine. Copyright Â
© 2013 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Carbapenemases; MLST; NDM; Palestine; Pseudomonas aeruginosa; VIM

Year:  2013        PMID: 27873597     DOI: 10.1016/j.jgar.2013.11.002

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  5 in total

1.  Genomic Characterization of VIM Metallo-β-Lactamase-Producing Alcaligenes faecalis from Gaza, Palestine.

Authors:  Nahed Al Laham; Kalyan D Chavda; Astrid V Cienfuegos-Gallet; Barry N Kreiswirth; Liang Chen
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

2.  Genetic Diversity, Biofilm Formation, and Antibiotic Resistance of Pseudomonas aeruginosa Isolated from Cow, Camel, and Mare with Clinical Endometritis.

Authors:  Samy F Mahmoud; Mahmoud Fayez; Ayman A Swelum; Amal S Alswat; Mohamed Alkafafy; Othman M Alzahrani; Saleem J Alsunaini; Ahmed Almuslem; Abdulaziz S Al Amer; Shaymaa Yusuf
Journal:  Vet Sci       Date:  2022-05-16

3.  First report of VIM metallo-β-lactamase production in Escherichia coli and Klebsiella pneumoniae clinical isolates from Gaza Strip, Palestine.

Authors:  Ghassan Tayh; Daram Nagarjuna; Rym Ben Sallem; Vivek Verma; Sarra Chairat; Abdellatif Boudabous; Manisha Yadav; Karim Ben Slama
Journal:  Germs       Date:  2020-03-02

4.  Prevalence and Characterization of Carbapenem-Hydrolyzing Class D β-Lactamase-Producing Acinetobacter Isolates From Ghana.

Authors:  Alafate Ayibieke; Ayumi Kobayashi; Masato Suzuki; Wakana Sato; Samiratu Mahazu; Isaac Prah; Miyuki Mizoguchi; Kyoji Moriya; Takaya Hayashi; Toshihiko Suzuki; Shiroh Iwanaga; Anthony Ablordey; Ryoichi Saito
Journal:  Front Microbiol       Date:  2020-11-13       Impact factor: 5.640

Review 5.  Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.

Authors:  Iman Dandachi; Amer Chaddad; Jason Hanna; Jessika Matta; Ziad Daoud
Journal:  Front Microbiol       Date:  2019-08-23       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.